JP2024543139A5 - - Google Patents

Info

Publication number
JP2024543139A5
JP2024543139A5 JP2024531129A JP2024531129A JP2024543139A5 JP 2024543139 A5 JP2024543139 A5 JP 2024543139A5 JP 2024531129 A JP2024531129 A JP 2024531129A JP 2024531129 A JP2024531129 A JP 2024531129A JP 2024543139 A5 JP2024543139 A5 JP 2024543139A5
Authority
JP
Japan
Prior art keywords
seq
antigen
binding protein
protein according
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024531129A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543139A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/080428 external-priority patent/WO2023097275A1/en
Publication of JP2024543139A publication Critical patent/JP2024543139A/ja
Publication of JP2024543139A5 publication Critical patent/JP2024543139A5/ja
Pending legal-status Critical Current

Links

JP2024531129A 2021-11-23 2022-11-23 抗ngf抗体及びその使用 Pending JP2024543139A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163282590P 2021-11-23 2021-11-23
US63/282,590 2021-11-23
US202263383173P 2022-11-10 2022-11-10
US63/383,173 2022-11-10
PCT/US2022/080428 WO2023097275A1 (en) 2021-11-23 2022-11-23 Anti-ngf antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024543139A JP2024543139A (ja) 2024-11-19
JP2024543139A5 true JP2024543139A5 (cg-RX-API-DMAC7.html) 2025-12-03

Family

ID=86540392

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024531129A Pending JP2024543139A (ja) 2021-11-23 2022-11-23 抗ngf抗体及びその使用

Country Status (8)

Country Link
US (3) US20250011410A1 (cg-RX-API-DMAC7.html)
EP (1) EP4436602A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024543139A (cg-RX-API-DMAC7.html)
KR (1) KR20240141160A (cg-RX-API-DMAC7.html)
AU (1) AU2022397400A1 (cg-RX-API-DMAC7.html)
CA (1) CA3238769A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024006267A (cg-RX-API-DMAC7.html)
WO (1) WO2023097275A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116096741B (zh) 2020-07-10 2024-10-18 因外泰克斯公司 用于延长治疗剂在猫科动物中的半衰期的组合物和使用方法
KR20250137204A (ko) 2022-12-27 2025-09-17 인베티엑스 인코포레이티드 신생아 fc 수용체(fcrn)에 대한 결합이 변경된 폴리펩타이드 및 사용 방법
AU2023415535A1 (en) 2022-12-27 2025-07-10 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
WO2025245092A1 (en) * 2024-05-20 2025-11-27 Invetx, Inc. Anti-ngf antibodies and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1575517T3 (da) * 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
US8082436B2 (en) 2008-07-08 2011-12-20 Dell Products L.P. Enhanced UEFI framework layer
SG187592A1 (en) * 2010-07-23 2013-03-28 Univ Boston Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
ES2665954T3 (es) * 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso
BR112020017701A2 (pt) * 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos
SG11202104120VA (en) * 2018-10-31 2021-05-28 Delinia Inc Multivalent regulatory t cell modulators
TW202237648A (zh) * 2020-11-18 2022-10-01 美商開拓免疫醫療公司 抗marco抗體及其用途

Similar Documents

Publication Publication Date Title
US20250051457A1 (en) Asgr inhibitors
Wang et al. Reshaping antibody diversity
Osbourn et al. Current methods for the generation of human antibodies for the treatment of autoimmune diseases
JP6587609B2 (ja) 強皮症治療のための抗ccl2及び抗loxl2併用療法
KR20140005864A (ko) 미오스타틴에 결합하는 항체, 조성물 및 방법
EP2761064B1 (en) Molecular display method
EP2836516B1 (en) Anti-adamts-5 antibody, derivatives and uses thereof
JP7858629B2 (ja) Fgfr3抗体および使用の方法
JP2021518168A (ja) 拮抗的抗原結合タンパク質
Qi et al. Pharmacological efficacy of anti-IL-1β scFv, Fab and full-length antibodies in treatment of rheumatoid arthritis
US20200397864A1 (en) Treating rotator cuff conditions
TW202000232A (zh) 用以治療或預防異位性骨化之醫藥組成物
JP7777831B2 (ja) Dnaポリメラーゼの5’→3’エキソヌクレアーゼ活性ドメインに特異的に結合する抗体
WO2016043577A1 (en) Ig-like molecules binding to bmp4
Xia et al. Anti-DNA antibody mediated catalysis is isotype dependent
CN113912728A (zh) 降低抗人白介素-33单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法
Shao et al. Specific recognition of a single-stranded RNA sequence by a synthetic antibody fragment
US20130130268A1 (en) Epitopes of the human pdgf receptor able to bind human auto-antibodies, antibodies and uses thereof
RU2528739C2 (ru) Способ получения пептидов, специфично распознающих определенные типы клеток и предназначенных для терапевтических целей
TW201726726A (zh) Asgr抑制劑
EP4442704A1 (en) Peptide having framework sequence for random region placement and peptide library composed of said peptide
Teplyakov et al. On the domain pairing in chimeric antibodies
CN117285621A (zh) 靶向sars-cov-2 s蛋白的抗原结合蛋白及其应用
WO2023121506A1 (ru) Средство и способ терапии заболеваний, вызываемых вирусом sars-cov-2
EP3356388A2 (en) Compounds binding to the fbg domain of tenascin and uses thereof